Introduction {#S0001}
============

Asthma is a chronic inflammatory disease of the airways that is characterized by variable airflow obstruction, increased airway responsiveness and inflammation, mucus overproduction, and airway remodeling \[[@CIT0001]\]. Asthma presents clinically as a result of combination of both genetic and environmental factors, and is the result of disrupted immune regulatory mechanisms occurring at the lymphocytic level in coordination with excess production of IgE antibodies resulting in allergic inflammatory reaction \[[@CIT0002]\].

One of the genes involved in the pathogenesis of bronchial asthma is NR3C1; its official name is a nuclear receptor subfamily 3, group C, member 1 (as determined by HUGO Gene Nomenclature Committee) that encodes glucocorticoid receptor (GCR) \[[@CIT0003]\].

The NR3C1 gene is localized on chromosome 5q31.3 and consists of nine exons \[[@CIT0003]\]. Exon 1 has seven basic transcriptional variants. Exons from 2 to 8 function as the core sequences of the *NR3C1* gene \[[@CIT0004]\]. Exon 9 determines two alternative splicing variants. The product of *NR3C1* gene expression is mRNA, which constitutes the basis for GCR isoforms formed as a result of alternative splicing (GCRα, GCRβ, GCRδ, GCRγ and GCR-P), among which only the α isoform is active. GCRβ is able to inhibit the signal pathway of isoform α and lead to impaired sensitivity to glucocorticosteroids \[[@CIT0005]\].

The GCR comprises 777 amino acids and five functional domains(AF1, activation domain 1; DBD, DNA binding domain; HR, hinge region; LBD, ligand-binding domain; and AF2, activation domain 2). The structure and biological activity of GCR domains is determined by the structure and nucleotide composition, among others, of the appropriate/corresponding exons of the NR3C1 gene, respectively: AF1 domain, exon 2; DBD domain, exons 3 and 4; HR and LBD domain, exons 5 to 9. Nucleotide changes in the DNA sequence of the analyzed gene may lead to gene transcription activation disturbances, changes in RNA splicing, changes in the secondary or tertiary structure of GCS receptor domains, translation initiation disturbances and disturbances of GCS receptor mRNA stability \[[@CIT0006], [@CIT0007]\]. The interactions of the GC/GCR complex and GC response element (GRE) may lead to selective activation or suppression of the target genes. The effect of GCs on the synthesis of proteins is determined by interactions with transcriptional enhancement sequences (GRE-positive) or transcriptional silencing sequences (GRE-negative). The GCR interacts directly with expression coactivators and corepressors for numerous genes. Therefore, the GCR is a particularly important element determining appropriate patient responses to exogenous GCs, which are the most important anti-inflammatory agents for controlling the course of bronchial asthma \[[@CIT0008]\]. As of today, 2571 polymorphisms of this gene are known, but the most common is the NR3C1 646 C\>G polymorphism \[[@CIT0008]\]. NR3C1 646 C\>G polymorphism was identified as a C/G substitution in intron 2, 646 nucleotides downstream from exon 2 \[[@CIT0009], [@CIT0010]\]. NR3C1 646 C\>G polymorphism significantly affects the process of alternative *NR3C1* gene splicing and within that mechanism increases the sensitivity to GCs \[[@CIT0011], [@CIT0012]\]. Other known SNPs of NR3C1 gene included Tth111I and ER22/23EK, N363S polymorphisms, which are also associated with altered glucocorticoid sensitivity. Tth111I polymorphism (rs10052957) is located in the area of the *NR3C1* gene promoter, 3807 bp upstream from the mRNA start site. It causes a C\>T substitution in the promoter region, that has been associated with enhanced basal cortisol levels \[[@CIT0013]\]. Yet another polymorphism has been described in exon 2, and it comprises two point mutations in codons 22 and 23 that are separated by 1 bp. The mutation in codon 22 is silent (GAG to GAA change, both coding for glutamic acid), whereas the codon 23 change from AGG to AAG results in an amino acid change from arginine to lysine (ER22/23EK) \[[@CIT0014]\]. Another variant is the single nucleotide polymorphism N363S, which is an AAT-to-AGT point mutation in exon 2 causing an asparagine to serine amino acid change in codon 363 \[[@CIT0015]\].

GCs resistant asthma is a complex problem, and to the present date, it is unknown whether it is inherited or acquired, and whether it is dependent on genetic or environmental factors \[[@CIT0002]\].

The aim of the present study was to determine the association between NR3C1 646 C\>G variation and resistance to GCs with development of severe asthma among Egyptians, a previously unstudied ethnic group.

Material and methods {#S0002}
====================

This study included 40 adult patients with severe bronchial asthma, who were recruited from the Allergy and Chest Diseases outpatient clinics at Ain Shams University Hospitals, Cairo. Asthma diagnosis was established according to GINA guidelines \[[@CIT0016]\]. All patients were subjected to a detailed medical history, clinical examination, and skin prick test (SPT). Atopy was defined by the presence of at least one positive SPT reaction to common environmental allergens including mites, animal epithelia, pollens, and molds. In addition, glucocorticoid (GCs) reversibility test was performed to differentiate between GCs sensitive and GCs resistant asthma.

Glucocorticoid reversibility test {#S20003}
---------------------------------

This was performed in the Pulmonary Functions Laboratory in Ain Shams University Hospital by spirometry to identify patients with GCs resistant asthma. Spirometry was carried out according to the standards of the European Respiratory Society (ERS) and the American thoracic Society (ATS) \[[@CIT0017]\]. Accordingly, asthmatic patients were subdivided into 2 subgroups: GCs sensitive asthmatic patients (*n* = 20); GCs resistant asthmatic patients (*n* = 20). *GCs resistant asthma* was defined as the failure of asthmatic patients to show an improvement in the forced expiratory volume in the first second (FEV~1~) by 15% after an adequate course of GCs (oral prednisolone 40 mg/d for 2 weeks) despite showing clear reversibility (\> 15%) to β~2~-agonists. On the other hand, *GCs sensitive asthma* was defined as patients who showed an improvement of 30% in FEV~1~ measurements after an equivalent dose of GCs.

Individuals who suffered from medication non-compliance, occupational asthma with ongoing antigenic exposure, gastro-esophageal reflux, aspirin or non steroid anti- inflammatory drugs (NSAIDs) sensitivity, food allergy, irreversible airflow obstruction and underlying systemic vasculitis were excluded from the study. Furthermore, patients using drugs which might induce resistance to GCs (including Rifampicin, Phenobarbital, Phenytoin, Ephedrine) and subjects with signs of viral infections, either generalized, or affecting the respiratory tract were excluded.

The study also included 20 apparently healthy individuals as a control group. All controls had no history of asthma or other allergic diseases and had no first-degree relatives with bronchial asthma or atopic disorders. In addition, all controls had normal spirometric lung functions and negative SPT reactions. An informed consent was obtained from all subjects, and the study was approved by the Research Ethics Committee of the Faculty of Medicine, Ain Shams University.

The glucocorticoid receptor gene polymorphism NR3C1 646 C\>G by PCR-RFLP {#S20004}
------------------------------------------------------------------------

This was evaluated for all patients and controls at the Clinical Pathology Department, Ain-Shams University Hospital as follows:

Sampling {#S20005}
--------

5 ml of venous blood were collected under aseptic conditions from every patient in a sterile EDTA vacutainer tube.

DNA Extraction {#S20006}
--------------

It was done using the QIAamp DNA Mini Kit supplied by Qiagen (Hilden, Germany). DNA in the sample was liberated using proteinase K solution and lysis buffer. Released DNA was bound exclusively and specifically to the QIAamp membrane in the presence of binding buffer under appropriate salt and pH conditions. Denatured protein and other contaminants were removed with several washing procedures. The DNA was then eluted from the membrane with elution buffer.

Polymerase chain reaction {#S20007}
-------------------------

For detection of NR3C1 646 C\>G polymorphism whose amplified product is 418 bp fragment, amplification was performed using a thermal cycler Gene Amp PCR system 9700 Applied biosystems. PCR product were carried out in volume of 50 µl containing 5 µl genomic DNA, 25 µl of the ready to use master mix supplied by Qiagen, 2.5 µl (25 pmol) of forward primer, 2.5 µl (25 pmol) of reverse primer and 15 µl of deionized water. Primers used were forward primer (5'-GAG AAA TTCACC CCT ACC AAC- 3') and a reverse primer (5'-AGAGCC CTA TTC TTC AAA CTG- 3'). The test primers were chosen according to Pietras *et al*. \[[@CIT0002]\] and prepared by Promega (Madison Wi, USA). PCR conditions were an initial denaturation step at 94°C for 3 minutes and 30 cycles consisting of denaturation at 94°C for 45 seconds, annealing at 60°C for 45 seconds, and extension at 72°C for 1 minute, then final extension at 72°C for 10 minutes.

Restriction fragment length polymorphism {#S20008}
----------------------------------------

Restriction digestion of the amplified product was performed using 1 µl (10 units/µl) *Bcl*-1 restriction enzyme supplied by Promega. The enzyme was added to 5 µl of PCR amplified product, 10 µL deionized water, 2 µl of buffer (10 × of 60 mM tris-Hcl) and 2 µl of acetylated bovine serum albumin (BSA) (10 µg/µl), followed by a gentle mix. Then the tubes were placed on a heat block for 2 hours at 50°C. The enzyme was inactivated at 65°C for 15 minutes. As experimental control: no-enzyme "mock" digest was used.

DNA analysis by gel electrophoresis {#S20009}
-----------------------------------

Amplified product of DNA samples and restriction fragments were run on 2% agarose gel (Promega) for 30 minutes at 100 V, stained with ethidium bromide (Amresco, Germany). 100 bp DNA ladder (Promega) was also run to identify the site of bands. The gel was examined under an ultraviolet transilluminator (Biometra, Germany).

Digestion of the amplified product resulted in the following products corresponding to the following 3 genotypes defined according to *Pietras et al.: homozygous CC genotype* if the band was divided into 2 parts: 263 and 155 bp; *homozygous GG genotype* if the band was not divided: 418 bp; *heterozygous GC genotype* if it yielded 3 bands: 418, 263 and 155 bp ([Fig. 1](#F0001){ref-type="fig"}) \[[@CIT0018]\].

![Agarose gel electrophoresis of NR3C1 646 C\>G fragments stained with ethidium bromide. Lane 1: 100 bp Ladder. Lane 2 represents unrestricted fragment, 1 band = 418 bp (experimental control: no enzyme "mock"). Lane 3 shows homozygous (GG) genotype, 1 band = 418 bp. Lane 4 shows heterozygous (GC) genotype, 3 bands = 418,263,155 bp. Lane 5 shows homozygous (CC) genotype, 2 bands = 263, 155 bp](CEJI-40-25875-g001){#F0001}

Statistical analysis {#S20010}
--------------------

Analysis of data was performed using the SPSS program version 17. Data were expressed as mean ± standard deviation (SD) for quantitative parametric measures and both number and percentage for categorical data. Student t-test was used for comparison between two independent groups for parametric data, whereas the one-way analysis of variance (ANOVA) test was used to compare the means of three groups. Comparison between qualitative variables was carried out by using χ^2^ test and Fisher\'s exact test. A *p*-value \< 0.05 was considered significant.

Results {#S0011}
=======

This study included 40 adult patients with severe bronchial asthma (23 females, 17 males). Severe asthmatic patients were subdivided into 2 subgroups: GCs sensitive asthmatic patients, n = 20; GCs resistant asthmatic patients (*n* = 20). Age, sex, and the atopic status were comparable among both subgroups. Significantly higher percentages of FEV~1~ were observed among GCs sensitive asthmatic patients after prednisolone therapy, as compared to GCs resistant asthmatic patients ([Table 1](#T0001){ref-type="table"}).

###### 

Characteristics of the study groups

  -----------------------------------------------------------------------------------------------------------------------------------------------
                                                GCs sensitive patient (n = 20)   GCs resistant patients (n = 20)   Controls (n = 20)   *p*
  --------------------------------------------- -------------------------------- --------------------------------- ------------------- ----------
  Age (y)[\*](#TF0001){ref-type="table-fn"}     43 ±8.2                          43 ±9.3                           40 ±5.3             0.410

  Sex, n (%)\                                   \                                \                                 \                   \
   Male\                                        8 (40)\                          9 (45)\                           7 (35)\             0.337
   Female                                       12 (60)                          11 (55)                           13 (65)             

  FEV1 (%)[\*](#TF0001){ref-type="table-fn"}\   \                                \                                 \                   \
   Before prednisolone\                         57 ±4.3\                         54.3 ±4.1\                        --\                 0.06\
   After prednisolone                           76.2 ±3.9                        56.45 ±3.8                        --                  \< 0.001

  Atopic status, n (%)\                         \                                \                                 \                   \
   Atopic\                                      12 (60)\                         15 (75)\                          --\                 0.311
   Non-atopic                                   8 (40)                           5 (25)                            --                  
  -----------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as mean standard deviation; FEV~1~ -- forced expiratory volume in 1^st^ second; GCs -- glucocorticoids

There was a highly significant difference in frequencies of NR3C1 646 C\>G genotypes and alleles between asthmatic patients and controls. The CC genotype was more frequent among asthmatic patients than among controls; the GG genotype was more frequent among controls than among asthmatic patients; whereas the GC genotype did not differ in distribution between asthmatic patients or controls. Moreover, almost all controls were G allele carriers in comparison to about two-thirds of asthmatic patients, whereas almost all asthmatic patients were C allele carriers ([Table 2](#T0002){ref-type="table"}).

###### 

Comparison between patients and controls regarding NR3C1 646 C\>G genotypes and alleles

  -----------------------------------------------------------------------------------------------------
  NR3C1 646 C\>G polymorphism                           Patients (n = 40)   Controls (n = 20)   *p*
  ----------------------------------------------------- ------------------- ------------------- -------
  Genotypes\                                            \                   \                   \
   GG\                                                  5 (12.5)\           9 (45)\             \
   GC\                                                  22 (55)\            10 (50)\            0.007
   CC                                                   13 (32.5)           1 (5)               

  G allele carriers[\*](#TF0002){ref-type="table-fn"}   27 (67.5)           19 (95)             0.023

  C allele carriers[¶](#TF0003){ref-type="table-fn"}    35 (87.5)           11 (55)             0.009
  -----------------------------------------------------------------------------------------------------

Subjects with GG or GC genotypes;

Subjects with CC or GC genotypes All values are presented as number (percentage)

[Table 3](#T0003){ref-type="table"} shows a significant difference in genotype distribution between GCs sensitive and GCs resistant asthmatics, with a greater frequency of the CC genotype distribution as well as C allele carriers among GCs sensitive asthmatics than among GCs resistant asthmatics.

###### 

Comparison between GCs sensitive and GCs resistant asthmatic patients regarding NR3C1 646 C\>G genotypes and alleles

  ------------------------------------------------------------------------------------------------------------------
  NR3C1 646 C\>G polymorphism                           GCs sensitive patients   GCs resistant patients   *p*
  ----------------------------------------------------- ------------------------ ------------------------ ----------
                                                        (n = 20)                 (n = 20)                 

  Genotypes\                                            \                        \                        \
   GG\                                                  0\                       5 (25)\                  \
   GC\                                                  11 (55)\                 11 (55)\                 0.028
   CC                                                   9 (45)                   4 (20)                   

  G allele carriers[\*](#TF0004){ref-type="table-fn"}   11 (55)                  16 (80)                  0.176

  C allele carriers[¶](#TF0005){ref-type="table-fn"}    20 (100)                 15 (75)                  \< 0.001
  ------------------------------------------------------------------------------------------------------------------

Subjects with GG or GC genotypes;

Subjects with CC or GC genotypes All values are presented as number (percentage); GCs, glucocorticoids

The frequencies of NR3C1 646 C\>G genotypes and alleles did not differ significantly according to the atopic status in GCs sensitive asthmatics ([Table 4](#T0004){ref-type="table"}) or in GCs resistant asthmatics ([Table 5](#T0005){ref-type="table"}).

###### 

Comparison between atopic and non-atopic GCs sensitive asthmatic patients regarding NR3C1 646 C\>G genotypes and alleles

  ----------------------------------------------------------------------------------------------------------------------
  NR3C1 646 C\>G polymorphism                           Atopic patients (n = 12)   Non-atopic patients (n = 8)   *p*
  ----------------------------------------------------- -------------------------- ----------------------------- -------
  Genotypes\                                            \                          \                             \
   GC\                                                  6 (50)\                    5 (62.5)\                     \
   CC                                                   6 (50)                     3 (37.5)                      0.362

  G allele carriers[\*](#TF0006){ref-type="table-fn"}   6 (50)                     5 (62.5)                      0.362

  C allele carriers[¶](#TF0007){ref-type="table-fn"}    12 (100)                   8 (100)                       1.0
  ----------------------------------------------------------------------------------------------------------------------

Subjects with GG or GC genotypes;

Subjects with CC or GC genotypes All values are presented as number (percentage); GCs, glucocorticoids

###### 

Comparison between atopic and non-atopic GCs resistant asthmatic patients regarding NR3C1 646 C\>G genotypes and alleles

  ----------------------------------------------------------------------------------------------------------------------
  NR3C1 646 C\>G polymorphism                           Atopic patients (n = 15)   Non-atopic patients (n = 5)   *p*
  ----------------------------------------------------- -------------------------- ----------------------------- -------
  Genotypes\                                            \                          \                             \
   GG\                                                  4 (26.7)\                  1 (20)\                       \
   GC\                                                  7 (46.7)\                  4 (80)\                       0.645
   CC                                                   4 (26.7)                   0                             

  G allele carriers[\*](#TF0008){ref-type="table-fn"}   11 (73.3)                  5 (100)                       0.530

  C allele carriers[¶](#TF0009){ref-type="table-fn"}    11 (73.3)                  4 (80)                        0.999
  ----------------------------------------------------------------------------------------------------------------------

Subjects with GG or GC genotypes;

Subjects with CC or GC genotypes All values are presented as number (percentage); GCs -- glucocorticoids

Discussion {#S0012}
==========

Despite the fact that GCs are widely used with great success in many inflammatory disorders including bronchial asthma, some patients show poor and sometimes no response to high doses. Difficult-to-treat asthma or GCs resistant asthma is explained by mutations of h-GCR gene, causing impairment of one or more of the molecular mechanisms of h-GR action leading to tissue non-responsiveness to GCs \[[@CIT0019]\].

Polymorphisms present within the h-GR/NR3C1 gene may inhibit formation of GR/GCs complexes, reduce transcription and cause transrepression of the genes encoding proteins synthesized within the framework of cellular response to GCs and decreased expression of GR that leads to a reduced response to GCs and impairment of GCR \[[@CIT0020]\]. GCs resistance is the main obstacle in many inflammatory diseases and therefore makes clinical management difficult \[[@CIT0021]\]

Among the several known functionally relevant alleles of the GCR are the alleles that comprise the NR3C1 646 C\>G. First discovered as a restriction fragment length polymorphism after digestion of GR DNA with *Bcl-1*, these alleles are determined by a single nucleotide variation -- cytosine (most common) or guanine -- in intron 2, 646 nucleotides downstream from exon 2. The allele containing cytosine is referred to as allele C, and the allele containing guanine as allele G, resulting in three possible genotypes at this position: homozygous CC, heterozygous GC and homozygous GG \[[@CIT0022]\].

NR3C1 646 C\>G polymorphism significantly affects the process of alternative NR3C1 gene splicing and within that mechanism increases the sensitivity to GCs \[[@CIT0018]\]. However, Manenschijn *et al*. observed that polymorphism is intronic, and that its location does not involve a coding, regulatory or splicing part of the GCR gene. Additionally, they suggested that this polymorphism is in linkage with other variations, e.g., in the promoter region, or linked to other functionally important polymorphisms \[[@CIT0023]\].

The aim of the present study was to determine the correlation between NR3C1 646 C\>G single nucleotide polymorphism of h-GR/NR3C1 gene and resistance to GCs therapy with the development of severe form/difficult- to-treat asthma. We demonstrated a statistically significant difference in genotype frequencies (GG genotype and CC genotype) of the NR3C1 646 C\>G polymorphism in all severe asthmatic patients compared with healthy controls; the CC genotype was more frequent in asthmatic patients compared with control subjects, while the GG genotype was less frequent in patients compared with control subjects. This finding is in disagreement with that observed by Pietras *et al*. who studied a group of Polish patients with severe asthma and observed significant differences between the investigated genotypes with a significant increase in the GG genotype among severe asthmatic patients compared to controls \[[@CIT0002]\].

Our findings are in line with Panek *et al*. who demonstrated a lower frequency of the NR3C1 646 C\>G GG homozygote and a higher frequency of the CC homozygote among asthmatics (which included mild, moderate, and severe asthmatics) in comparison to the control group. However, the authors observed no statistically significant differences in frequencies of NR3C1 646 C\>G polymorphism when severe asthma was compared with the control group \[[@CIT0018]\]. The discrepancy between their findings and our results may be attributed in part to our relatively smaller sample size.

In the present study, there was a significant difference in allelic frequencies of the NR3C1 646 C\>G polymorphism in asthmatic patients compared to controls. C allele carriers were more frequent among asthmatic patients, whereas G allele carriers were more frequent among healthy controls. This finding is in contrast with that observed by Pietras *et al*. who observed a significant difference in allelic frequency regarding the G allele between asthmatic patients and controls but no significant difference in allelic frequency regarding the C allele between asthmatic patients and controls.

In addition, the current study showed a significant difference in NR3C1 646 C\>G genotypes and alleles frequencies between GCs sensitive and GCs resistant asthmatics. We demonstrated that GCs sensitive asthmatics had a greater frequency of the CC genotype distribution as well as C allele carriers than GCs resistant asthmatics. This finding is also in contrast with that observed by Pietras *et al*., who demonstrated that allele G is particularly associated with sensitivity to GCs, and that it increases the cellular response to GCs and occurs less frequently than allele C \[[@CIT0002]\]. This discrepancy could be attributed to different population ethnicity.

Atopy is considered one of the important risk factors in the pathogenesis of asthma. In turn, antigen-specific IgE produced in a sequence of immune processes is essential for atopy to occur. One review explained the role of environmental agents in the modulation of these immune processes, and therefore, modulation in asthma development \[[@CIT0024]\]. The few studies available on the association between NR3C1 646 C\>G single nucleotide polymorphism of h-GR/NR3C1 gene promoter and resistance to GCs therapy with development of severe form/ difficult-to-treat asthma have not addressed the relationship with atopy. To our knowledge, we report here for the first time that there is no relationship between atopy and this gene polymorphism. Further large-scale studies on larger numbers of atopic asthmatics should be carried out to investigate this relationship.

Conclusions {#S0013}
===========

The presented study is a preliminary stage for more profound analysis of association between the prevalence of the particular allelic variants of the h-GR/NR3C1 gene and the development of bronchial asthma, including severe, treatment-resistant forms of the disease. It should be emphasized that no studies concerning the frequency of h-GR/NR3C1 glucocorticoid receptor gene polymorphisms in atopic asthmatics patients have been conducted to date.
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